On July 17, Intuitive Surgical declined over 10% overnight, trading at $359.00/share, with turnover of $11,900. The sell-off was triggered after the company reported Q2 fiscal results that beat Wall Street expectations but failed to raise full-year guidance, while management flagged persistent challenges in the China market.

Specifically, Intuitive Surgical posted Q2 adjusted earnings of $2.80 per diluted share, surpassing the analyst consensus estimate of $2.50 by 12%, and revenue of $2.89 billion versus the $2.83 billion expected. Global da Vinci procedure volume grew 15% year-over-year in the quarter. However, the company merely maintained its full-year global procedure growth guidance of 13.5% to 15.5%, expecting actual growth near the midpoint, without any upward revision despite the strong quarter.

Additionally, management noted that the China market environment remains challenging, citing intensifying domestic robotics competition and policy-driven pricing pressure. The combination of unraised guidance and China concerns prompted profit-taking, particularly after the stock had rallied 3.16% intraday ahead of the earnings release amid a broader medical device sector rebound.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)